Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study

Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

(2021) Yu Chen et al.   Annals of Translational Medicine

Original study: EGFR Exon 20 Insertion Mutations: clinicopathological characteristics and treatment outcomes in advanced non-small-cell lung cancer

(2021) Jose Luis Leal et al.   Clinical Lung Cancer

First‐Line Osimertinib in Patients with EGFR ‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

(2021) Martina Lorenzi et al.   ONCOLOGIST

Genomic landscape of lung adenocarcinoma in East Asians

(2020) Jianbin Chen et al.   NATURE GENETICS

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer

(2020) Chen Lin et al.   Frontiers in Oncology

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)

(2020) Connor O’Leary et al.   Pharmaceuticals

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

(2019) Hirokazu Taniguchi et al.   Nature Communications

BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer

(2019) Wenxia Su et al.   MEDICINE

Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance

(2019) Santoni-Rugiu et al.   Cancers

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

(2019) Chenjing Zhu et al.   Molecular Cancer

Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

(2018) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment

(2018) Jan Nyrop Jakobsen et al.   Oncotarget

Common Co-activation of AXL and CDCP1 in EGFR -mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis

(2018) Niki Karachaliou et al.   EBioMedicine

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Thanyanan Reungwetwattana et al.   JOURNAL OF CLINICAL ONCOLOGY

Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.

(2018) Zofia Piotrowska et al.   Cancer Discovery

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

(2018) Nicolas Marcoux et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers

(2018) Michael Offin et al.   CLINICAL CANCER RESEARCH

Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC?

(2018) Michael L. Cheng et al.   CLINICAL CANCER RESEARCH

Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients

(2017) Nicholas T. Gimbrone et al.   Journal of Thoracic Oncology

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

(2017) Collin M Blakely et al.   NATURE GENETICS

Tracking the Evolution of Non–Small-Cell Lung Cancer

(2017) Mariam Jamal-Hanjani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

(2017) Emmet J. Jordan et al.   Cancer Discovery

EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer

(2017) Xueli Nan et al.   Oncotarget

Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients

(2017) Lijun Dong et al.   Oncotarget

Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations

(2017) Joshua D. Campbell et al.   JAMA Oncology

EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non–Small Cell Lung Cancer Patients

(2016) Yong Won Choi et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Drug Resistance to EGFR Inhibitors in Lung Cancer

(2016) Osamu Tetsu et al.   CHEMOTHERAPY

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

(2016) Jun Wang et al.   OncoTargets and Therapy

Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis

(2015) Feng-Che Kuan et al.   BRITISH JOURNAL OF CANCER

Epidermal Growth Factor Receptor–Mutant Lung Cancer

(2015) Zofia Piotrowska et al.   CANCER JOURNAL

Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas

(2015) Zhenzhou Wu et al.   HUMAN PATHOLOGY

Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell Lung Cancer

(2015) Guanshan Zhu et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)

(2015) Oscar Arrieta et al.   Journal of Thoracic Oncology

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

(2015) Niki Karachaliou et al.   Scientific Reports

AXL Mediates Resistance to Cetuximab Therapy

(2014) T. M. Brand et al.   CANCER RESEARCH

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

(2014) G. R. Oxnard et al.   CLINICAL CANCER RESEARCH

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

(2014) C. Costa et al.   CLINICAL CANCER RESEARCH

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

(2012) H. Thorvaldsdottir et al.   BRIEFINGS IN BIOINFORMATICS

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells

(2012) Keisuke Tabara et al.   PLoS One

Incidence ofEGFRExon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas

(2011) Sandra P. D'Angelo et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrative genomics viewer

(2011) James T Robinson et al.   NATURE BIOTECHNOLOGY

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

(2010) K. Suda et al.   CLINICAL CANCER RESEARCH

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

(2009) David Jackman et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients

(2008) J P Koivunen et al.   BRITISH JOURNAL OF CANCER

Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals

(2008) Jian-quan Zhu et al.   CANCER LETTERS